Several therapeutic agents have been developed for HER2/neu positive breast cancer: these include monoclonal antibodies such as trastuzumab and pertuzumab, small molecule tyrosine kinase inhibitors like lapatinib, and chemo-immunotherapy conjugates like ado-trastuzumab emtansine (T-DM1). This evidence concerns the gene ERBB2 and breast cancer.